Clinical Trial Update: Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain [Phase 3]

View source ↗

Summary

This clinical trial update reports on the safety and tolerability findings from a Phase 3 study of Egalet-002 in adults with moderate-to-severe chronic noncance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pain

Drugs mentioned

• Egalet-002

Snippet

Sponsor: Egalet Ltd | Conditions: Moderate-to-severe Chronic Noncancer Pain | Phase 3 | Status: COMPLETED